Sugi Predict

Sugi Predict / Targets / PTPRE

PTPRE

Receptor-type tyrosine-protein phosphatase epsilon · P23469 · PTPRE on Sugi Atlas →

1,609 patent compounds predicted against PTPRE, 1,037 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4318827 SCHEMBL4318827 1.00 4/20
SCHEMBL6318130 SCHEMBL6318130 1.00 4/20
SCHEMBL5443077 SCHEMBL5443077 0.59 4/20
SCHEMBL5442863 SCHEMBL5442863 0.51 4/20
SCHEMBL5435664 SCHEMBL5435664 0.48 4/20
SCHEMBL4311266 SCHEMBL4311266 0.61 3/20
SCHEMBL5450981 SCHEMBL5450981 0.54 3/20
SCHEMBL5444273 SCHEMBL5444273 0.53 3/20
SCHEMBL5444496 SCHEMBL5444496 0.50 3/20
SCHEMBL6310639 SCHEMBL6310639 0.46 3/20
SCHEMBL4312414 SCHEMBL4312414 1.00 2/20
SCHEMBL5837972 SCHEMBL5837972 1.00 2/20
SCHEMBL3468827 SCHEMBL3468827 0.76 2/20
SCHEMBL4361861 SCHEMBL4361861 0.76 2/20
SCHEMBL5741314 SCHEMBL5741314 0.75 2/20
SCHEMBL3760411 SCHEMBL3760411 0.67 2/20
SCHEMBL6315134 SCHEMBL6315134 0.67 2/20
SCHEMBL3467221 SCHEMBL3467221 0.65 2/20
SCHEMBL4293286 SCHEMBL4293286 0.65 2/20
SCHEMBL244007 SCHEMBL244007 0.65 2/20

Clinical trials — most relevant to PTPRE by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) PHASE1/PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Erythropoietin Therapy for Subarachnoid Hemorrhage PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer PHASE2COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Erlotinib and Metformin in Triple Negative Breast Cancer PHASE1COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Cardiovascular Effects of Empagliflozine nanUNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Prospective Monocentric Clinical-biological Database nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPRE binder may also engage these)

ProteinNameSimilarity
B2GV87 — 1.000 B2GV87 →
P49446 — 1.000 P49446 →
PTPRA Receptor-type tyrosine-protein phosphatase alpha 0.998 landscape →
Q03348 — 0.995 Q03348 →
P35234 — 0.993 P35234 →
P18052 — 0.990 P18052 →
Q641Z2 — 0.985 Q641Z2 →
PTPN7 Tyrosine-protein phosphatase non-receptor type 7 0.985 landscape →
P49445 — 0.984 P49445 →
PTPN6 Tyrosine-protein phosphatase non-receptor type 6 0.984 landscape →
P29351 — 0.984 P29351 →
Q5I143 — 0.983 Q5I143 →
Q5I145 — 0.982 Q5I145 →
O35239 — 0.982 O35239 →
PTPN9 Tyrosine-protein phosphatase non-receptor type 9 0.981 landscape →
Q5I142 — 0.981 Q5I142 →
Q8BUM3 — 0.981 Q8BUM3 →
P41499 — 0.980 P41499 →
Q5I141 — 0.980 Q5I141 →
P35235 — 0.979 P35235 →
P81718 — 0.978 P81718 →
Q90687 — 0.977 Q90687 →
PTPN11 Tyrosine-protein phosphatase non-receptor type 11 0.977 landscape →
P28202 — 0.976 P28202 →
Q5I127 — 0.974 Q5I127 →
P28219 — 0.974 P28219 →
A2ALK8 — 0.974 A2ALK8 →
PTPN3 Tyrosine-protein phosphatase non-receptor type 3 0.974 landscape →
Q60629 — 0.973 Q60629 →
Q5I147 — 0.973 Q5I147 →